155 related articles for article (PubMed ID: 36971076)
1. Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals.
Tuncay G; Damadoglu E; Cihanbeylerden M; Can Bostan O; Kayıkcı H; Özer S; Karakaya G; Kalyoncu AF
J Asthma; 2023 Oct; 60(10):1885-1894. PubMed ID: 36971076
[TBL] [Abstract][Full Text] [Related]
2. [Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : Results of a multicentric study].
Staufenberg AR; Frankenberger HK; Förster-Ruhrmann U; Spahn FC; Klimek L; Fruth K; Stihl C; Matthias C; Gröger M; Hagemann J
HNO; 2024 Jul; 72(7):473-483. PubMed ID: 38466409
[TBL] [Abstract][Full Text] [Related]
3. [The value of aspirin challenge tests in the diagnosis of non-steroidal anti-inflammatory drugs-exacerbated respiratory disease].
Xiao H; Zhang L; Lin H; Xiao YL; Zhang HT; Jia QR; Xu F; Meng J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Aug; 58(8):741-746. PubMed ID: 37550033
[No Abstract] [Full Text] [Related]
4. [Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics?].
Klimek F; Förster-Ruhrmann U; Hagemann J; Cuevas M; Gröger M; Klimek L
HNO; 2024 Jul; 72(7):484-493. PubMed ID: 38409556
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
Cihanbeylerden M; Tuncay G; Kayıkçı H; Damadoglu E; Karakaya G; Kalyoncu AF
Int Arch Allergy Immunol; 2024 Jun; ():1-6. PubMed ID: 38865992
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 300 mg versus 600 mg daily maintenance doses of aspirin treatment after desensitization in N-ERD: A three-year multicentre experience.
Celik GE; Karakaya G; Erkekol FO; Dursun AB; Gelincik A; Aydin O; Damadoglu E; Yucel T; Yorulmaz I; Dursun E; Buyukatalay ZC; Sozener ZC; Buyukozturk S; Kalyoncu AF
Allergy Asthma Proc; 2023 Mar; 44(2):106-114. PubMed ID: 36872443
[No Abstract] [Full Text] [Related]
7. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.
Sánchez J; García E; Lopez JF; Calle A; Buendia JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2172-2179. PubMed ID: 37146885
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.
Tan JHY; Hsu AAL
Respir Med; 2016 Sep; 118():1-3. PubMed ID: 27578463
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease.
Wongsa C; Sompornrattanaphan M; Tantilipikorn P; Thongngarm T
Asian Pac J Allergy Immunol; 2022 Sep; 40(3):247-253. PubMed ID: 31677617
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.
Sweis AM; Locke TB; Ig-Izevbekhai KI; Lin TC; Kumar A; Douglas JE; Corr AM; Civantos AM; Tripathi SH; Kennedy DW; Kohanski MA; Palmer JN; Adappa ND; Bosso JV
Allergy Asthma Proc; 2021 Mar; 42(2):136-141. PubMed ID: 33685558
[No Abstract] [Full Text] [Related]
11. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
Cho KS; Soudry E; Psaltis AJ; Nadeau KC; McGhee SA; Nayak JV; Hwang PH
Otolaryngol Head Neck Surg; 2014 Oct; 151(4):575-81. PubMed ID: 25118195
[TBL] [Abstract][Full Text] [Related]
12. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.
Mullur J; Steger CM; Gakpo D; Bensko JC; Maurer R; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 May; 128(5):575-582. PubMed ID: 35131410
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents.
Ertoy Karagol HI; Yilmaz O; Topal E; Ceylan A; Bakirtas A
Int Forum Allergy Rhinol; 2015 May; 5(5):392-8. PubMed ID: 25755210
[TBL] [Abstract][Full Text] [Related]
14. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
15. High Discontinuation Rates of Peroral ASA Treatment for CRSwNP: A Real-World Multicenter Study of 171 N-ERD Patients.
Laulajainen-Hongisto A; Turpeinen H; Vento SI; Numminen J; Sahlman J; Kauppi P; Virkkula P; Hytönen M; Toppila-Salmi S
J Allergy Clin Immunol Pract; 2020; 8(10):3565-3574. PubMed ID: 32693216
[TBL] [Abstract][Full Text] [Related]
16. Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD.
Tepetam FM; Özden Ş; Kılıç FK; Örçen C; Yakut T
World Allergy Organ J; 2023 Sep; 16(9):100817. PubMed ID: 37771938
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
Quint T; Dahm V; Ramazanova D; Arnoldner MA; Kurz H; Janik S; Brunner PM; Knerer-Schally B; Weninger W; Griss J; Ristl R; Schneider S; Bangert C
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):506-516.e6. PubMed ID: 34678497
[TBL] [Abstract][Full Text] [Related]
18. Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease.
Aydin Ö; Atmiş EÖ; Anadolu Y; Yorulmaz İ; Çelik GE
J Asthma; 2023 Jun; 60(6):1131-1140. PubMed ID: 36218308
[TBL] [Abstract][Full Text] [Related]
19. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.
Morales DR; Guthrie B; Lipworth BJ; Jackson C; Donnan PT; Santiago VH
Allergy; 2015 Jul; 70(7):828-35. PubMed ID: 25855099
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
